Neogen (NEOG) Competitors

$8.19 -0.24 (-2.85%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$8.20 +0.01 (+0.06%)

As of 05/15/2026 05:12 PM Eastern

NEOG vs. MMSI, ICUI, HAE, XRAY, and STAA

Should you buy Neogen stock or one of its competitors? MarketBeat compares Neogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neogen include Merit Medical Systems (MMSI), ICU Medical (ICUI), Haemonetics (HAE), DENTSPLY SIRONA (XRAY), and STAAR Surgical (STAA). These companies are all part of the "health care supplies" industry.

How does Neogen compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

In the previous week, Merit Medical Systems had 6 more articles in the media than Neogen. MarketBeat recorded 12 mentions for Merit Medical Systems and 6 mentions for Neogen. Merit Medical Systems' average media sentiment score of 1.24 beat Neogen's score of 1.20 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merit Medical Systems	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Merit Medical Systems has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merit Medical Systems	$1.54B	2.37	$128.49M	$2.31	26.56
Neogen	$894.66M	1.99	-$1.09B	-$2.80	N/A

Merit Medical Systems has a net margin of 9.03% compared to Neogen's net margin of -69.93%. Merit Medical Systems' return on equity of 13.54% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merit Medical Systems	9.03%	13.54%	7.94%
Neogen	-69.93%	2.35%	1.46%

Merit Medical Systems currently has a consensus target price of $92.80, indicating a potential upside of 51.24%. Neogen has a consensus target price of $10.67, indicating a potential upside of 30.24%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, equities analysts clearly believe Merit Medical Systems is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merit Medical Systems	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Merit Medical Systems has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Neogen has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market.

99.7% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 0.7% of Merit Medical Systems shares are owned by company insiders. Comparatively, 0.6% of Neogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Merit Medical Systems beats Neogen on 15 of the 16 factors compared between the two stocks.

How does Neogen compare to ICU Medical?

Neogen (NASDAQ:NEOG) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, ICU Medical had 5 more articles in the media than Neogen. MarketBeat recorded 11 mentions for ICU Medical and 6 mentions for Neogen. Neogen's average media sentiment score of 1.20 beat ICU Medical's score of 0.41 indicating that Neogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ICU Medical	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$894.66M	1.99	-$1.09B	-$2.80	N/A
ICU Medical	$2.23B	1.33	$730K	$1.85	64.17

ICU Medical has a net margin of 2.15% compared to Neogen's net margin of -69.93%. ICU Medical's return on equity of 7.50% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-69.93%	2.35%	1.46%
ICU Medical	2.15%	7.50%	3.91%

Neogen presently has a consensus target price of $10.67, suggesting a potential upside of 30.24%. ICU Medical has a consensus target price of $169.00, suggesting a potential upside of 42.35%. Given ICU Medical's stronger consensus rating and higher probable upside, analysts clearly believe ICU Medical is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
ICU Medical	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Neogen has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, ICU Medical has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

96.7% of Neogen shares are held by institutional investors. Comparatively, 96.1% of ICU Medical shares are held by institutional investors. 0.6% of Neogen shares are held by insiders. Comparatively, 2.1% of ICU Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ICU Medical beats Neogen on 12 of the 16 factors compared between the two stocks.

How does Neogen compare to Haemonetics?

Haemonetics (NYSE:HAE) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Haemonetics presently has a consensus target price of $79.33, suggesting a potential upside of 40.81%. Neogen has a consensus target price of $10.67, suggesting a potential upside of 30.24%. Given Haemonetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Haemonetics is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Haemonetics had 1 more articles in the media than Neogen. MarketBeat recorded 7 mentions for Haemonetics and 6 mentions for Neogen. Neogen's average media sentiment score of 1.20 beat Haemonetics' score of 0.04 indicating that Neogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neogen	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 1.8% of Haemonetics shares are held by company insiders. Comparatively, 0.6% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Haemonetics has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	1.96	$97.31M	$2.02	27.89
Neogen	$894.66M	1.99	-$1.09B	-$2.80	N/A

Haemonetics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Neogen has a beta of 1.84, suggesting that its stock price is 84% more volatile than the broader market.

Haemonetics has a net margin of 7.29% compared to Neogen's net margin of -69.93%. Haemonetics' return on equity of 27.30% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.29%	27.30%	9.59%
Neogen	-69.93%	2.35%	1.46%

Summary

Haemonetics beats Neogen on 14 of the 17 factors compared between the two stocks.

How does Neogen compare to DENTSPLY SIRONA?

DENTSPLY SIRONA (NASDAQ:XRAY) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

DENTSPLY SIRONA presently has a consensus target price of $13.82, suggesting a potential upside of 37.22%. Neogen has a consensus target price of $10.67, suggesting a potential upside of 30.24%. Given DENTSPLY SIRONA's higher possible upside, equities analysts clearly believe DENTSPLY SIRONA is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DENTSPLY SIRONA	3 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Neogen had 2 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 6 mentions for Neogen and 4 mentions for DENTSPLY SIRONA. DENTSPLY SIRONA's average media sentiment score of 1.20 beat Neogen's score of 1.20 indicating that DENTSPLY SIRONA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DENTSPLY SIRONA	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.7% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by company insiders. Comparatively, 0.6% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DENTSPLY SIRONA has higher revenue and earnings than Neogen. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DENTSPLY SIRONA	$3.68B	0.55	-$598M	-$3.15	N/A
Neogen	$894.66M	1.99	-$1.09B	-$2.80	N/A

DENTSPLY SIRONA has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Neogen has a beta of 1.84, suggesting that its stock price is 84% more volatile than the broader market.

DENTSPLY SIRONA has a net margin of -17.06% compared to Neogen's net margin of -69.93%. DENTSPLY SIRONA's return on equity of 18.83% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DENTSPLY SIRONA	-17.06%	18.83%	5.13%
Neogen	-69.93%	2.35%	1.46%

Summary

DENTSPLY SIRONA and Neogen tied by winning 8 of the 16 factors compared between the two stocks.

How does Neogen compare to STAAR Surgical?

STAAR Surgical (NASDAQ:STAA) and Neogen (NASDAQ:NEOG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

STAAR Surgical has a net margin of -7.24% compared to Neogen's net margin of -69.93%. STAAR Surgical's return on equity of 3.31% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STAAR Surgical	-7.24%	3.31%	2.55%
Neogen	-69.93%	2.35%	1.46%

In the previous week, STAAR Surgical had 24 more articles in the media than Neogen. MarketBeat recorded 30 mentions for STAAR Surgical and 6 mentions for Neogen. Neogen's average media sentiment score of 1.20 beat STAAR Surgical's score of 0.53 indicating that Neogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STAAR Surgical	5 Very Positive mention(s)	8 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Neogen	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

STAAR Surgical presently has a consensus target price of $27.81, suggesting a potential downside of 13.28%. Neogen has a consensus target price of $10.67, suggesting a potential upside of 30.24%. Given Neogen's stronger consensus rating and higher possible upside, analysts plainly believe Neogen is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STAAR Surgical	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

STAAR Surgical has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Neogen has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market.

96.7% of STAAR Surgical shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 39.9% of STAAR Surgical shares are held by company insiders. Comparatively, 0.6% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

STAAR Surgical has higher earnings, but lower revenue than Neogen. STAAR Surgical is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STAAR Surgical	$239.44M	6.67	-$80.45M	-$0.43	N/A
Neogen	$894.66M	1.99	-$1.09B	-$2.80	N/A

Summary

STAAR Surgical beats Neogen on 9 of the 16 factors compared between the two stocks.

Get Neogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEOG vs. The Competition

Export

Metric	Neogen	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.78B	$8.02B	$6.37B	$12.30B
Dividend Yield	N/A	2.52%	2.80%	5.26%
P/E Ratio	-2.93	15.79	20.66	25.27
Price / Sales	1.99	7.36	532.07	62.46
Price / Cash	1.42	16.48	42.43	54.86
Price / Book	0.86	3.78	9.87	6.90
Net Income	-$1.09B	$223.05M	$3.57B	$334.66M
7 Day Performance	-9.50%	-3.49%	0.23%	0.12%
1 Month Performance	-13.88%	-2.59%	-2.54%	-0.18%
1 Year Performance	23.90%	-0.20%	33.54%	30.62%

Neogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEOG Neogen	2.3774 of 5 stars	$8.19 -2.8%	$10.67 +30.2%	+23.9%	$1.78B	$894.66M	N/A	2,110	Positive News
MMSI Merit Medical Systems	4.1323 of 5 stars	$60.31 -1.6%	$92.80 +53.9%	-37.9%	$3.66B	$1.52B	26.11	7,500
ICUI ICU Medical	3.5268 of 5 stars	$124.68 -1.4%	$169.00 +35.5%	-16.0%	$3.16B	$2.23B	67.39	13,000	News Coverage Insider Trade
HAE Haemonetics	4.1099 of 5 stars	$52.32 -5.1%	$79.89 +52.7%	-20.0%	$2.56B	$1.33B	25.90	3,023	Analyst Forecast
XRAY DENTSPLY SIRONA	4.6871 of 5 stars	$10.91 -0.8%	$13.82 +26.7%	-39.7%	$2.20B	$3.68B	N/A	14,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEOG) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neogen (NEOG) Competitors

NEOG vs. MMSI, ICUI, HAE, XRAY, and STAA

How does Neogen compare to Merit Medical Systems?

Summary

How does Neogen compare to ICU Medical?

Summary

How does Neogen compare to Haemonetics?

Summary

How does Neogen compare to DENTSPLY SIRONA?

Summary

How does Neogen compare to STAAR Surgical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neogen (NEOG) Competitors

NEOG vs. MMSI, ICUI, HAE, XRAY, and STAA

How does Neogen compare to Merit Medical Systems?

Does the media refer more to MMSI or NEOG?

Which has better earnings & valuation, MMSI or NEOG?

Is MMSI or NEOG more profitable?

Do analysts rate MMSI or NEOG?

Which has more risk & volatility, MMSI or NEOG?

Do institutionals & insiders have more ownership in MMSI or NEOG?

Summary

How does Neogen compare to ICU Medical?

Does the media prefer NEOG or ICUI?

Which has stronger earnings & valuation, NEOG or ICUI?

Is NEOG or ICUI more profitable?

Do analysts prefer NEOG or ICUI?

Which has more volatility & risk, NEOG or ICUI?

Do insiders and institutionals have more ownership in NEOG or ICUI?

Summary

How does Neogen compare to Haemonetics?

Do analysts prefer HAE or NEOG?

Does the media prefer HAE or NEOG?

Do institutionals and insiders have more ownership in HAE or NEOG?

Which has higher valuation and earnings, HAE or NEOG?

Which has more risk & volatility, HAE or NEOG?

Is HAE or NEOG more profitable?

Summary

How does Neogen compare to DENTSPLY SIRONA?

Do analysts prefer XRAY or NEOG?

Does the media prefer XRAY or NEOG?

Do institutionals and insiders have more ownership in XRAY or NEOG?

Which has higher valuation and earnings, XRAY or NEOG?

Which has more risk & volatility, XRAY or NEOG?

Is XRAY or NEOG more profitable?

Summary

How does Neogen compare to STAAR Surgical?

Is STAA or NEOG more profitable?

Does the media favor STAA or NEOG?

Do analysts prefer STAA or NEOG?

Which has more risk and volatility, STAA or NEOG?

Do insiders & institutionals have more ownership in STAA or NEOG?

Which has stronger valuation & earnings, STAA or NEOG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools